Floatz logo

Human T-Lymphocyte Activation Antigen Cd80 (Activation B7-1 Antigen, Ctla-4 Counter-Receptor B7.1, Cd80) Extracellular Domain Containing Fragment (1-208 In The Current Sequence) Fused Via Peptide Linker <Sup>209</Sup>Gsggggsggggsggggs<Sup>225</Sup> To An Fc Fragment Of Human Immunoglobulin G4 (226-454) [Homo Sapiens Ighg4*01, Hinge Ins<Sup>226</Sup>>A, S<Sup>236</Sup>>P (226-238), Ch2 F<Sup>242</Sup>>A, L<Sup>243</Sup>>A, T<Sup>258</Sup>>Q (239-348), Ch3 M<Sup>436</Sup>>L (349-453), Chs K<Sup>455</Sup>>Del (454)] Fused Via Peptide/ Linker <Sup>455</Sup>Ggggs<Sup>459</Sup> To Human Interleukin-2 (Il-2, T-Cell Growth Factor (Tcgf)) (1-133, 460-592 In The Current Sequence), Variant (R<Sup>38</Sup>>A<Sup>497</Sup>, F<Sup>42</Sup>>A<Sup>501</Sup>), Dimer (234-234', 237-237')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Glycoform Alfa

Urothelial Carcinoma

Explore 163 assets in Urothelial Carcinoma →
Floatz Rating
CC43/100
Confidence
Indicative
v0.2
Sponsor
GI Innovation, Inc.
Modality
protein_peptide
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT04977453CT.gov
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
—Recruiting———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Urothelial Carcinoma

AssetSponsorPhaseRating
Human T-Lymphocyte Activation Antigen Cd80 (Activation B7-1 Antigen, Ctla-4 Counter-Receptor B7.1, Cd80) Extracellular Domain Containing Fragment (1-208 In The Current Sequence) Fused Via Peptide Linker <Sup>209</Sup>Gsggggsggggsggggs<Sup>225</Sup> To An Fc Fragment Of Human Immunoglobulin G4 (226-454) [Homo Sapiens Ighg4*01, Hinge Ins<Sup>226</Sup>>A, S<Sup>236</Sup>>P (226-238), Ch2 F<Sup>242</Sup>>A, L<Sup>243</Sup>>A, T<Sup>258</Sup>>Q (239-348), Ch3 M<Sup>436</Sup>>L (349-453), Chs K<Sup>455</Sup>>Del (454)] Fused Via Peptide/ Linker <Sup>455</Sup>Ggggs<Sup>459</Sup> To Human Interleukin-2 (Il-2, T-Cell Growth Factor (Tcgf)) (1-133, 460-592 In The Current Sequence), Variant (R<Sup>38</Sup>>A<Sup>497</Sup>, F<Sup>42</Sup>>A<Sup>501</Sup>), Dimer (234-234', 237-237')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Glycoform Alfa (this asset)GI Innovation, Inc.P1/2CC · 43
CyclophosphamideBeijing BiotechP3BB
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)Vasgene Therapeutics, IncP2/3BB
DurvalumabAlliance for Clinical Trials in OncologyP3BB
Cis-Diamminedichloroplatinum IiNagoya UniversityP3BB
PembrolizumabSutro Biopharma, Inc.P3BB
Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, DimerEli Lilly and CompanyP3BB
RetifanlimabIncyte CorporationP2BB
DocetaxelNuCana plcP3BB

+42 more in the Urothelial Carcinoma cohort

Other indications for Human T-Lymphocyte Activation Antigen Cd80 (Activation B7-1 Antigen, Ctla-4 Counter-Receptor B7.1, Cd80) Extracellular Domain Containing Fragment (1-208 In The Current Sequence) Fused Via Peptide Linker <Sup>209</Sup>Gsggggsggggsggggs<Sup>225</Sup> To An Fc Fragment Of Human Immunoglobulin G4 (226-454) [Homo Sapiens Ighg4*01, Hinge Ins<Sup>226</Sup>>A, S<Sup>236</Sup>>P (226-238), Ch2 F<Sup>242</Sup>>A, L<Sup>243</Sup>>A, T<Sup>258</Sup>>Q (239-348), Ch3 M<Sup>436</Sup>>L (349-453), Chs K<Sup>455</Sup>>Del (454)] Fused Via Peptide/ Linker <Sup>455</Sup>Ggggs<Sup>459</Sup> To Human Interleukin-2 (Il-2, T-Cell Growth Factor (Tcgf)) (1-133, 460-592 In The Current Sequence), Variant (R<Sup>38</Sup>>A<Sup>497</Sup>, F<Sup>42</Sup>>A<Sup>501</Sup>), Dimer (234-234', 237-237')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Glycoform Alfa

IndicationSponsorPhaseRating
Nonpapillary Renal Cell Carcinoma—P1/2CCC · 48
Non-Small Cell Squamous Lung Carcinoma—P1/2CCC · 48
Cervical Cancer—P1/2CC · 41

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Human T-Lymphocyte Activation Antigen Cd80 (Activation B7-1 Antigen, Ctla-4 Counter-Receptor B7.1, Cd80) Extracellular Domain Containing Fragment (1-208 In The Current Sequence) Fused Via Peptide Linker <Sup>209</Sup>Gsggggsggggsggggs<Sup>225</Sup> To An Fc Fragment Of Human Immunoglobulin G4 (226-454) [Homo Sapiens Ighg4*01, Hinge Ins<Sup>226</Sup>>A, S<Sup>236</Sup>>P (226-238), Ch2 F<Sup>242</Sup>>A, L<Sup>243</Sup>>A, T<Sup>258</Sup>>Q (239-348), Ch3 M<Sup>436</Sup>>L (349-453), Chs K<Sup>455</Sup>>Del (454)] Fused Via Peptide/ Linker <Sup>455</Sup>Ggggs<Sup>459</Sup> To Human Interleukin-2 (Il-2, T-Cell Growth Factor (Tcgf)) (1-133, 460-592 In The Current Sequence), Variant (R<Sup>38</Sup>>A<Sup>497</Sup>, F<Sup>42</Sup>>A<Sup>501</Sup>), Dimer (234-234', 237-237')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Glycoform Alfa in Urothelial Carcinoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/human-t-lymphocyte-activation-antigen-cd80-activation-b7-1-antigen-ctla-4-counter-receptor-b71-cd80-extracellular-domain-containing-fragment-1-208-in-the-current-sequence-fused-via-peptide-linker-sup209supgsggggsggggsggggssup225sup-to-an-fc-fragment-of-human-immunoglobulin-g4-226-454-homo-sapiens-ighg401-hinge-inssup226supa-ssup236supp-226-238-ch2-fsup242supa-lsup243supa-tsup258supq-239-348-ch3-msup436supl-349-453-chs-ksup455supdel-454-fused-via-peptide-linker-sup455supggggssup459sup-to-human-interleukin-2-il-2-t-cell-growth-factor-tcgf-1-133-460-592-in-the-current-sequence-variant-rsup38supasup497sup-fsup42supasup501sup-dimer-234-234-237-237-bisdisulfide-produced-in-chinese-hamster-ovary-cho-cells-glycoform-alfa-urothelial-carcinoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →